Lite Strategy, Inc. Segments Disclosure
Note 12. Segment Information
Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the CODM, which is our Acting , in deciding how to allocate resources and assess performance. Our CODM evaluates our financial information including year over year profit and loss comparisons and cash projections on an aggregate basis when assessing performance for allocating financial and personnel resources. We are not organized by market and are managed and operated as one business.
We identify our operating segments based on our business activities. We operate within a operating segment, the development of pharmaceutical products. During fiscal 2025, we did not generate any revenue. During fiscal 2024, all revenues were generated in the United States. Our administrative functions including finance, business development and information systems, support the development of pharmaceutical products segment. We operate in one geographic area, the United States. The CODM allocates resources (inclusive of both capital and personnel) based upon our net loss, which is utilized to monitor year over year variances on a quarterly basis.
The accounting policies of the development of pharmaceutical products segment are the same as those described in Note 2. Summary of Significant Accounting Policies. All our assets are in the United States. The measure of segment assets is reported on the balance sheets as total assets. We do not have intra-entity sales or transfers.
During the years ended, June 30, 2025 and 2024, we had no transactions denominated in foreign currencies nor any intangible property for which we recognized amortization expense. During the years ended June 30, 2025 and 2024, we did recognize depreciation expense which we have included in "other expenses" within the table below. Depreciation expense is reported in our statements of cash flows and is expected to be zero during fiscal 2026. Non-cash expenses such as depreciating assets and share-based compensation are not part of the CODM's evaluation or decision-making process.
The following table summarizes our financial data for the development of pharmaceutical products segment:
|
|
For the Fiscal Year Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Revenues |
|
$ |
— |
|
|
$ |
65,297 |
|
|
|
|
|
|
|
|
||
Operating and other (income) expense |
|
|
|
|
|
|
||
Employee expenses |
|
|
9,293 |
|
|
|
13,207 |
|
Other segment expenses(1) |
|
|
2,647 |
|
|
|
9,946 |
|
Professional fees |
|
|
2,754 |
|
|
|
4,092 |
|
Legal fees |
|
|
1,723 |
|
|
|
3,397 |
|
Impairment of long-lived assets |
|
|
— |
|
|
|
10,899 |
|
Fees paid on behalf of a related party |
|
|
— |
|
|
|
1,118 |
|
voruciclib |
|
|
801 |
|
|
|
3,413 |
|
ME-344 |
|
|
253 |
|
|
|
4,724 |
|
Gain on disposition of a non-financial asset |
|
|
(500 |
) |
|
|
— |
|
Interest and dividend income |
|
|
(1,026 |
) |
|
|
(3,277 |
) |
Total operating and other (income) expense |
|
|
15,945 |
|
|
|
47,519 |
|
Total segment costs (loss) income and net (loss) income |
|
$ |
(15,945 |
) |
|
$ |
17,778 |
|
________
(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Sep 26, 2025 | Showing above |
| 2022 | Sep 8, 2022 | |
| 2021 | Sep 2, 2021 | |
| 2020 | Sep 9, 2020 | |
| 2019 | Aug 28, 2019 | |
| 2018 | Aug 30, 2018 | |
| 2017 | Sep 5, 2017 | |
| 2016 | Sep 6, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.